SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025

JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis senior leadership team will participate in the H.C. Wainwright 27^th Annual Global Conference.

Date: Wednesday September 10, 2025
Format: In-person presentation and 1x1 meetings
Time: 10:30 a.m.-11:00 a.m. ET
Location: New York, NY

If you are interested in scheduling a 1x1 meeting, please reach out to your H.C. Wainwright representative.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in clinical, pre- clinical and discovery phases, including the compound SCY-247. For more information, visit www.scynexis.com.

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com